Is Heparin could block the COVID-19 Viral infection? Researchers Identified !
Heparin
Heparin is an anticoagulant (i.e: blood thinner/loosener) that prevents the formation of blood clots caused by certain serious injury( Trauma), prolonged sitting, pregnancy , smoking and certain medical procedure. It also used before surgery to prevents or reduce the risk of blood clots.
It is also known as unfractionated heparin (UFH) is a medication and it was naturally occuring Glycosaminoglycans(GAGs or Mucopolysaccharides consisting repeated number of disaccharides units It is highly polar and attract water, they are used in the bidy as shock absorber)
Mechanism
The mechanism based on antithrombin (AT) dependent mechaanism. Heparin bound to enzyme inhibitor antithrombin(AT) III through its high affinity pentasaccharide causing a conformational change in AT leads to its activation , the activated AT then inactivates thrombin, factor Xa and other proteases. This leads to inhibition of converting prothrombin to thrombin
History
It was first discovered by Jay McLean and Wiliam Henry Howell in 1916, although it didn't enter into the clinical trials untill 1935. It was originally isolated from dog liver cells. Mc lean was working under the guidance of Howell ,when he isolated a fat- soluble phosphatide anticoagulant in dog liver tissue. In 1918 he coined the term "Heparin". In the 1935, Erik Jorpes published the structure of heparin.
Heparin neutralise the COVID - 19
According to antiviral researchers published this week, Heparin may also be a powerful tool in fighting COVID 19. SARS-CoV-2, the virus that causes COVID 19, uses spike protein to penetrate into human cells and starts infection. But heparin binds to the surface spike protein and would potentially blocking the infection from happening. It might be introduces into the body using a nasal spray or nebulizer and run interference to lower the odds of infection.
Robert Linhardt (lead author and professor of chemistry and chemical biology at Rensselaer Institute) said " this approach could be used as an early intervention to reduce the infection to the peoples who have tested positive , but aren't yet suffering symptoms. But we also see this as a part of larger antiviral strategy" and also said "we can able to controll the virus until the vaccine is found".
To infect a cell, a virus must penetrate into the specific target on the cell surface,by the cell membrane and insert its own genetic codes into the host DNA and hijacking the cellular process within to produce replicated viruses. But the virus could easily be induce to lock onto a decoy molecule, provided that, this molecule offers the same fit as the cellular target. Once bound to a decoy, the virus would be neutralised and unable to infect a cell or free itself and leads to eventually degrade...
In humans SARS- CoV-2 binds to an ACE-2 receptor, and the researchers hypothesized that heparin would offer an equally attractive target. in a binding assay, the researchers found that, heparin bound to the trimeric SARS CoV 2 spike protein at 73 picomoles, a measure of the interaction between the two molecules.
Jonathan Dordick , a chemical and biological engineering professor at Rensselaer Institute who is working with Linhardt to develop the "Decoy Strategy" said the binding was extremely tight binding , once it binds it's not able to come off...
- https://smartpharmainfo.blogspot.com/2020/07/biophore-india-to-get-approval-for.html
- https://smartpharmainfo.blogspot.com/2020/07/itolizumab-for-treatment-of-covid-19.html
- https://smartpharmainfo.blogspot.com/2020/07/bubonic-plague.html
- https://smartpharmainfo.blogspot.com/2020/07/covaxin-explanation-by.html
- https://smartpharmainfo.blogspot.com/2020/06/what-is-dactylography.html
No comments:
Get more Medical news, updates &information from www.smartpharmainfo.blogspot.com
Keep support my blog....